| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -5.5 | -0.4 |
| EPS (diluted, $ a share) | $-0.49 | $-0.58 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ELOX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Eloxx Pharmaceuticals, Inc.: key numbers
- Share price
- $11.74Close, Nov 17
- Market cap
- $48M
- Shares outstanding
- 4.09MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Eloxx Pharmaceuticals, Inc.
All →Eloxx Pharmaceuticals Financial Results
Eloxx Pharmaceuticals reported Q3 2026 financial results and provided a business update on its rare kidney disease pipeline, including the dosing of the first two patients in the Phase 2b EXACT study for Alport syndrome. The company also received FDA IND clearance for its Phase 2 EXPRESS study in ADPKD and ended the quarter with $56.3 million in cash.
- Term
- Q3 2026
“The third quarter marked important progress for Eloxx, as we dosed the first two patients in our Phase 2b EXACT study in nonsense mutation Alport syndrome. With the EXPRESS protocol finalized and IND clearance in hand, we now have two programs in rare kidney disease.”
Sumit Aggarwal, President and Chief Executive Officer
Eloxx Pharmaceuticals Leadership Change
Eloxx Pharmaceuticals has expanded its Board of Directors from five to six members and appointed Geno J. Germano as an independent director. Mr. Germano is a 35-year pharmaceutical industry veteran who previously served as CEO of Elucida Oncology and Group President at Pfizer. He will serve a term expiring at the company's 2027 annual meeting of stockholders.